Abstract: Ingestible devices are disclosed that provide very high localization accuracy for the devices when present in the GI tract of a body. Related systems and methods are also disclosed.

Abstract: A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.

Abstract: An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

Abstract: This disclosure features methods and devices for treating diseases with orally-delivered biotherapeutics.

Abstract: Ingestible devices are disclosed that provide very high localization accuracy for the devices when present in the GI tract of a body. Related systems and methods are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a live biothcrapeutic.

Abstract: The present disclosure relates to gastrointestinal (Gl) tract microbiome detection and manipulation devices, systems, and methods. The determination of antimicrobial susceptibility of a micro-organism within the gastrointestinal tract involves identifying an antimicrobial agent that inhibits the growth of the micro-organism has been disclosed, which has been obtained from a sample having been removed from an ingestible device that retrieved the sample from the Gl tract of the subject. A test to identify the micro-organism can be included. Treatment methods related to small intestinal bacterial overgrowth (SIBO), a SIBO-related condition, or symptomology suggestive of SIBO in a subject in need thereof, involving orally administering an effective amount of a pharmaceutical formulation comprising an antimicrobial agent to the subject are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a SMAD7 inhibitor.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.